In­vestor 'misalign­men­t' leads to tR­NA biotech's shut­ter­ing

A small biotech look­ing to carve a lane in the tR­NA field has fold­ed, an in­vestor and a co-founder con­firmed to End­points News.

Sim­i­lar to Flag­ship’s All­tr­na and oth­er up­starts like Take­da-backed hC Bio­science, the now-shut­tered Theonys was at­tempt­ing to go af­ter trans­fer RNA, seen as a po­ten­tial Swiss Army knife in the broad­er RNA ther­a­peu­tics space. The idea is that one tR­NA drug could be used across a galaxy of dis­or­ders and dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER